In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease (original) (raw)

Abstract

In a Flemish kindred, an Ala(692)-->Gly amino acid substitution in the amyloid beta-protein precursor (AbetaPP) causes a form of early-onset Alzheimer's disease (AD) which displays prominent amyloid angiopathy and unusually large senile plaque cores. The mechanistic basis of this Flemish form of AD is unknown. Previous in vitro studies of amyloid beta-protein (Abeta) production in HEK-293 cells transfected with cDNA encoding Flemish AbetaPP have shown that full-length [Abeta(1-40)] and truncated [Abeta(5-40) and Abeta(11-40)] forms of Abeta are produced. In an effort to determine how these peptides might contribute to the pathogenesis of the Flemish disease, comparative biophysical and neurotoxicity studies were performed on wild-type and Flemish Abeta(1-40), Abeta(5-40) and Abeta(11-40). The results revealed that the Flemish amino acid substitution increased the solubility of each form of peptide, decreased the rate of formation of thioflavin-T-positive assemblies, and increased the SDS-stability of peptide oligomers. Although the kinetics of peptide assembly were altered by the Ala(21)-->Gly substitution, all three Flemish variants formed fibrils, as did the wild-type peptides. Importantly, toxicity studies using cultured primary rat cortical cells showed that the Flemish assemblies were as potent a neurotoxin as were the wild-type assemblies. Our results are consistent with a pathogenetic process in which conformational changes in Abeta induced by the Ala(21)-->Gly substitution would facilitate peptide adherence to the vascular endothelium, creating nidi for amyloid growth. Increased peptide solubility and assembly stability would favour formation of larger deposits and inhibit their elimination. In addition, increased concentrations of neurotoxic assemblies would accelerate neuronal injury and death.

Full Text

The Full Text of this article is available as a PDF (254.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem. 1992 Jan 5;267(1):546–554. [PubMed] [Google Scholar]
  2. Clements A., Allsop D., Walsh D. M., Williams C. H. Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease. J Neurochem. 1996 Feb;66(2):740–747. doi: 10.1046/j.1471-4159.1996.66020740.x. [DOI] [PubMed] [Google Scholar]
  3. Clements A., Walsh D. M., Williams C. H., Allsop D. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid beta/A4 peptide. Neurosci Lett. 1993 Oct 14;161(1):17–20. doi: 10.1016/0304-3940(93)90129-9. [DOI] [PubMed] [Google Scholar]
  4. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E., Lansbury P. T., Jr Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):571–576. doi: 10.1073/pnas.97.2.571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cras P., van Harskamp F., Hendriks L., Ceuterick C., van Duijn C. M., Stefanko S. Z., Hofman A., Kros J. M., Van Broeckhoven C., Martin J. J. Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala-->Gly mutation. Acta Neuropathol. 1998 Sep;96(3):253–260. doi: 10.1007/s004010050892. [DOI] [PubMed] [Google Scholar]
  6. De Jonghe C., Zehr C., Yager D., Prada C. M., Younkin S., Hendriks L., Van Broeckhoven C., Eckman C. B. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis. 1998 Oct;5(4):281–286. doi: 10.1006/nbdi.1998.0202. [DOI] [PubMed] [Google Scholar]
  7. El-Agnaf O. M., Guthrie D. J., Walsh D. M., Irvine G. B. The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide. Eur J Biochem. 1998 Sep 15;256(3):560–569. doi: 10.1046/j.1432-1327.1998.2560560.x. [DOI] [PubMed] [Google Scholar]
  8. Esler W. P., Stimson E. R., Ghilardi J. R., Lu Y. A., Felix A. M., Vinters H. V., Mantyh P. W., Lee J. P., Maggio J. E. Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence. Biochemistry. 1996 Nov 5;35(44):13914–13921. doi: 10.1021/bi961302+. [DOI] [PubMed] [Google Scholar]
  9. Ewbank D. C. Deaths attributable to Alzheimer's disease in the United States. Am J Public Health. 1999 Jan;89(1):90–92. doi: 10.2105/ajph.89.1.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fabian H., Szendrei G. I., Mantsch H. H., Otvos L., Jr Comparative analysis of human and Dutch-type Alzheimer beta-amyloid peptides by infrared spectroscopy and circular dichroism. Biochem Biophys Res Commun. 1993 Feb 26;191(1):232–239. doi: 10.1006/bbrc.1993.1207. [DOI] [PubMed] [Google Scholar]
  11. Fraser P. E., Nguyen J. T., Inouye H., Surewicz W. K., Selkoe D. J., Podlisny M. B., Kirschner D. A. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid beta-protein. Biochemistry. 1992 Nov 10;31(44):10716–10723. doi: 10.1021/bi00159a011. [DOI] [PubMed] [Google Scholar]
  12. Glenner G. G., Wong C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984 May 16;120(3):885–890. doi: 10.1016/s0006-291x(84)80190-4. [DOI] [PubMed] [Google Scholar]
  13. Haass C., Hung A. Y., Selkoe D. J., Teplow D. B. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem. 1994 Jul 1;269(26):17741–17748. [PubMed] [Google Scholar]
  14. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997 Apr;20(4):154–159. doi: 10.1016/s0166-2236(96)01030-2. [DOI] [PubMed] [Google Scholar]
  15. Harper J. D., Lansbury P. T., Jr Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997;66:385–407. doi: 10.1146/annurev.biochem.66.1.385. [DOI] [PubMed] [Google Scholar]
  16. Harper J. D., Wong S. S., Lieber C. M., Lansbury P. T. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol. 1997 Feb;4(2):119–125. doi: 10.1016/s1074-5521(97)90255-6. [DOI] [PubMed] [Google Scholar]
  17. Hartley D. M., Kurth M. C., Bjerkness L., Weiss J. H., Choi D. W. Glutamate receptor-induced 45Ca2+ accumulation in cortical cell culture correlates with subsequent neuronal degeneration. J Neurosci. 1993 May;13(5):1993–2000. doi: 10.1523/JNEUROSCI.13-05-01993.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hartley D. M., Walsh D. M., Ye C. P., Diehl T., Vasquez S., Vassilev P. M., Teplow D. B., Selkoe D. J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 1999 Oct 15;19(20):8876–8884. doi: 10.1523/JNEUROSCI.19-20-08876.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hendriks L., van Duijn C. M., Cras P., Cruts M., Van Hul W., van Harskamp F., Warren A., McInnis M. G., Antonarakis S. E., Martin J. J. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet. 1992 Jun;1(3):218–221. doi: 10.1038/ng0692-218. [DOI] [PubMed] [Google Scholar]
  20. Ida N., Hartmann T., Pantel J., Schröder J., Zerfass R., Förstl H., Sandbrink R., Masters C. L., Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem. 1996 Sep 13;271(37):22908–22914. doi: 10.1074/jbc.271.37.22908. [DOI] [PubMed] [Google Scholar]
  21. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1550–1555. doi: 10.1073/pnas.94.4.1550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kamino K., Orr H. T., Payami H., Wijsman E. M., Alonso M. E., Pulst S. M., Anderson L., O'dahl S., Nemens E., White J. A. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet. 1992 Nov;51(5):998–1014. [PMC free article] [PubMed] [Google Scholar]
  23. Kumar-Singh S., Dewachter I., Moechars D., Lübke U., De Jonghe C., Ceuterick C., Checler F., Naidu A., Cordell B., Cras P. Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Neurobiol Dis. 2000 Feb;7(1):9–22. doi: 10.1006/nbdi.1999.0272. [DOI] [PubMed] [Google Scholar]
  24. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., Morgan T. E., Rozovsky I., Trommer B., Viola K. L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448–6453. doi: 10.1073/pnas.95.11.6448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Larner A. J. Hypothesis: amyloid beta-peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease. Neurobiol Aging. 1999 Jan-Feb;20(1):65–69. doi: 10.1016/s0197-4580(99)00014-7. [DOI] [PubMed] [Google Scholar]
  26. Levy E., Carman M. D., Fernandez-Madrid I. J., Power M. D., Lieberburg I., van Duinen S. G., Bots G. T., Luyendijk W., Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 1990 Jun 1;248(4959):1124–1126. doi: 10.1126/science.2111584. [DOI] [PubMed] [Google Scholar]
  27. Lomakin A., Teplow D. B., Kirschner D. A., Benedek G. B. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):7942–7947. doi: 10.1073/pnas.94.15.7942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Maat-Schieman M. L., van Duinen S. G., Bornebroek M., Haan J., Roos R. A. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): II--A review of histopathological aspects. Brain Pathol. 1996 Apr;6(2):115–120. doi: 10.1111/j.1750-3639.1996.tb00794.x. [DOI] [PubMed] [Google Scholar]
  29. Melchor J. P., McVoy L., Van Nostrand W. E. Charge alterations of E22 enhance the pathogenic properties of the amyloid beta-protein. J Neurochem. 2000 May;74(5):2209–2212. doi: 10.1046/j.1471-4159.2000.0742209.x. [DOI] [PubMed] [Google Scholar]
  30. Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., Cotman C. W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 1993 Apr;13(4):1676–1687. doi: 10.1523/JNEUROSCI.13-04-01676.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pike C. J., Overman M. J., Cotman C. W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem. 1995 Oct 13;270(41):23895–23898. doi: 10.1074/jbc.270.41.23895. [DOI] [PubMed] [Google Scholar]
  32. Roos R. A., Haan J., Van Broeckhoven C. Hereditary cerebral hemorrhage with amyloidosis--Dutch type: a congophilic angiopathy. An overview. Ann N Y Acad Sci. 1991;640:155–160. doi: 10.1111/j.1749-6632.1991.tb00208.x. [DOI] [PubMed] [Google Scholar]
  33. Selkoe D. J. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem. 1996 Aug 2;271(31):18295–18298. doi: 10.1074/jbc.271.31.18295. [DOI] [PubMed] [Google Scholar]
  34. Selkoe D. J. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998 Nov;8(11):447–453. doi: 10.1016/s0962-8924(98)01363-4. [DOI] [PubMed] [Google Scholar]
  35. Selkoe D. J. The molecular pathology of Alzheimer's disease. Neuron. 1991 Apr;6(4):487–498. doi: 10.1016/0896-6273(91)90052-2. [DOI] [PubMed] [Google Scholar]
  36. Sian A. K., Frears E. R., El-Agnaf O. M., Patel B. P., Manca M. F., Siligardi G., Hussain R., Austen B. M. Oligomerization of beta-amyloid of the Alzheimer's and the Dutch-cerebral-haemorrhage types. Biochem J. 2000 Jul 1;349(Pt 1):299–308. doi: 10.1042/0264-6021:3490299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Soreghan B., Kosmoski J., Glabe C. Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. J Biol Chem. 1994 Nov 18;269(46):28551–28554. [PubMed] [Google Scholar]
  38. Tekirian T. L., Yang A. Y., Glabe C., Geddes J. W. Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of A beta1-40 and -42. J Neurochem. 1999 Oct;73(4):1584–1589. doi: 10.1046/j.1471-4159.1999.0731584.x. [DOI] [PubMed] [Google Scholar]
  39. Van Nostrand W. E., Melchor J. P., Ruffini L. Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. J Neurochem. 1998 Jan;70(1):216–223. doi: 10.1046/j.1471-4159.1998.70010216.x. [DOI] [PubMed] [Google Scholar]
  40. Walsh D. M., Hartley D. M., Kusumoto Y., Fezoui Y., Condron M. M., Lomakin A., Benedek G. B., Selkoe D. J., Teplow D. B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999 Sep 3;274(36):25945–25952. doi: 10.1074/jbc.274.36.25945. [DOI] [PubMed] [Google Scholar]
  41. Walsh D. M., Lomakin A., Benedek G. B., Condron M. M., Teplow D. B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997 Aug 29;272(35):22364–22372. doi: 10.1074/jbc.272.35.22364. [DOI] [PubMed] [Google Scholar]
  42. Wang Z., Natté R., Berliner J. A., van Duinen S. G., Vinters H. V. Toxicity of Dutch (E22Q) and Flemish (A21G) mutant amyloid beta proteins to human cerebral microvessel and aortic smooth muscle cells. Stroke. 2000 Feb;31(2):534–538. doi: 10.1161/01.str.31.2.534. [DOI] [PubMed] [Google Scholar]
  43. Watson D. J., Selkoe D. J., Teplow D. B. Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. Biochem J. 1999 Jun 15;340(Pt 3):703–709. [PMC free article] [PubMed] [Google Scholar]
  44. Wisniewski T., Ghiso J., Frangione B. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1247–1254. doi: 10.1016/0006-291x(91)91706-i. [DOI] [PubMed] [Google Scholar]
  45. Zhang S., Casey N., Lee J. P. Residual structure in the Alzheimer's disease peptide: probing the origin of a central hydrophobic cluster. Fold Des. 1998;3(5):413–422. doi: 10.1016/S1359-0278(98)00054-6. [DOI] [PubMed] [Google Scholar]